On Apr. 22, 2025, Regeneron Pharmaceuticals announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s commercial biologic medicines at their Holly Springs, North Carolina
campus.

Regeneron will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm’s new state-of-the-art biopharmaceutical facility. With technology transfer beginning immediately and a ten-year term, the total investment is estimated to exceed $3 billion.

This new investment underscores Regeneron’s commitment to deliver innovative medicines to patients. Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

In addition, the company is constructing a brand new, state-of-the-art fill/finish manufacturing facility in Rensselaer, New York , and has acquired an over 1 million-square foot property in Saratoga Springs, New York, for production support activities and, potentially, additional manufacturing capacity.

The company’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.